rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

BioStem Technologies, Inc.

BSEM · Nasdaq

Health CareBiotechnologyNot moving yet

BSEM stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 47.1% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
0

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1$0$1Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders0
New · exited0 · 0
Reported value$0

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange

Everyone who traded it

Jason Matuszewski Company insiderChief Executive Officer · last 7 Oct 20260 · 0
Vurst Andrew Smith-Van Company insiderChief Operating Officer · last 7 Oct 20260 · 0
Brandon Poe Company insiderChief Financial Officer · last 15 Sep 20260 · 0
Kenneth Howard Warrington Jr. Company insiderDirector · last 15 Sep 20260 · 0
Michael A. Fortunato Company insiderChief Accounting Officer · last 15 Sep 20260 · 0
Barry Hassett Company insiderChief Commercial Officer · last 9 Sep 20260 · 0
Hannaway Rayna Lesser Company insiderDirector · last 27 Aug 20260 · 0
Jodi Ungrodt Company insiderDirector · last 27 Aug 20260 · 0
Mark A. Glickman Company insiderDirector · last 27 Aug 20260 · 0
Steven D. Sonenreich Company insiderDirector · last 27 Aug 20260 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

No ratio computed from its SEC filings yet.

Analyst forecasts

No analyst forecasts yet.